PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23022224-3	2012	Pharmacokinetic evaluation of (64)Cu-DOTA-VEGF(121)/rGel showed relatively high blood retention 30 min after injection (26.6 +- 1.73% ID/g), dropping to 11.8 +- 2.83% and 0.82 +- 0.11% ID/g at 60 and 240 min post injection, respectively.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	34-41	vascular endothelial growth factor A	Mus musculus	42-46	
22406249-2	2012	Pre-treatment microPET images were acquired on SKOV-3 cell-implanted nude mice after injection with (64)Cu-DOTA-VEGF(121).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	104-111	vascular endothelial growth factor A	Mus musculus	112-116	
22406249-4	2012	After injections occurred daily for 28 days, all groups of mice underwent post-treatment microPET imaging after injection with (64)Cu-DOTA-VEGF(121).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	131-138	vascular endothelial growth factor A	Mus musculus	139-143	
21070475-5	2011	Tumor accumulation of (64)Cu-DOTA-bevacizumab was significantly correlated with VEGF expression as measured by western blot (rho = 0.81, P = 0.004).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	26-33	vascular endothelial growth factor A	Mus musculus	80-84	
21070475-8	2011	The present study successfully showed (64) Cu-DOTA-bevacizumab as a potential PET tracer for non-invasive imaging of VEGF expression in colorectal cancer xenografts.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	43-50	vascular endothelial growth factor A	Mus musculus	117-121